Drilling at Mt Mansbridge. Source: Red Mountain Mining Mining
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Red Mountain Mining (RMX) records assays of up to 0.316 per cent total rare earth oxide (TREO) at its Mt Mansbridge project in the Eastern Kimberly
  • The company says the presence of yttrium, dysprosium and terbium suggest the mineralisation is xenotime, a rare-earth phosphate mineral
  • Remaining assays from drilling are expected this quarter; petrological analysis results are also expected within the coming weeks
  • The company says following the wet season, completion of reverse circulation drilling at Mt Mansbridge is scheduled for Q2 2022
  • Shares were trading at 1 cent at previous close on January 5

Red Mountain Mining (RMX) has recorded assays of up to 0.316 per cent total rare earth oxide (TREO) at its Mt Mansbridge project in the Eastern Kimberley region of Western Australia.

Located within the project, the Solo prospect assays showed an average ratio of heavy rare earth oxide to TREO of 66.62 per cent.

Drilling has confirmed the presence of rare earths in particular a large distribution of Yttrium. The company also says the dominance of dysprosium and terbium suggests the mineralisation is xenotime, a rare-earth phosphate mineral. The remaining assays from drilling are expected this quarter.

Meanwhile, petrological analysis is currently being undertaken by Diamantina Laboratories, with results anticipated in the coming weeks.

Red Mountain Mining said it successfully completed four of the planned holes at the project, before the drill rig and personnel demobilised from the site, due to the onset of the wet season within the Kimberley.

Following the wet season, the company is planning to complete reverse circulation drilling at Mt Mansbridge which is scheduled for Q2 2022.

Shares were trading at 1 cent at previous close on January 5.

RMX by the numbers
More From The Market Herald

" PointsBet (ASX:PBH) losses extend to $51.8m

PointsBet (ASX:PBH) has reported $51.8 million in cash outflows for its quarterly update as the company…
Imugene (ASX:IMU) - CEO, Leslie Chong

" Imugene (ASX:IMU) signs clinical trial agreement with Roche for lung cancer

Imugene (ASX:IMU) signs a clinical trial supply agreement with Roche to evaluate the combination of treatments…
Fiji Kava (ASZ:FIJ) - CEO and Managing Director, Dr Anthony Noble

" Fiji Kava (ASX:FIJ) hits quarterly revenue record

Fiji Kava (ASX:FIJ) has tabled a record quarterly revenue of $476,531 for the December quarter, up…
Imagion Biosystems (ASX:IBX) - CEO & Executive Chairman, Bob Proulx

" Imagion (ASX:IBX) ends 2021 on an “upbeat note”

Imagion Biosytems (ASX:IBX) finishes 2021 on an "upbeat note" as it progresses with its MagSense HER2…